At this in-person event, we'll share insights around the recent USP, PDA, and Ph. Eur updates and what they mean for pharma packaging professionals.
What are the recent regulatory updates?
- USP has changed their definition of a Type 1 glass and this now includes packaging made using new glass types, not just borosilicate.
- PDA has updated its classifications of defects in empty glass containers – some of which have increased in severity whilst others have decreased.
So we’ll explore both of these areas at our upcoming Future of pharma glass packaging forum to help you make better informed packaging choices and stay ahead of the curve.
Other topics include how pharma glass waste can be reduced and recycled, identifying delamination (and its early signs), and what to do when you find breakages on the line.
This session is ideal for packaging technologists and quality assurance professionals. It offers a blend of content – including insights about what each regulation update means for your business and knowledge-sharing presentations on how you can ensure your product packaging is fit for purpose.
Tickets are £149 each
(only 40 spots available).
The agenda for the day:
- Introduction to Glass Technology Services
- Overview of the regulatory updates: USP <660> PF issue 49(4) IRA official January 1, 2024.
- We will discuss how these updates affect your packaging choices now you have more flexibility, inspection criteria and how to address non-conformances.
- The benefits of using new, novel “type 1” vials which are not borosilicate.
- What is delamination and its early signs? Support on the best packaging choices to avoid delamination.
- What to do when you find breakages on the line. How fracture analysis will help identify key stages in processes to improve.
- The future of pharma glass packaging – how we can reduce waste, opportunities for recycling, and innovations using borosilicate glass.